Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Chronic Myeloproliferative Disorders - Kidney Cancer - Leukemia - Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms - Neuroblastoma - Oral Complications - Ovarian Cancer - Pain - Sarcoma
Conditions: official terms
Multiple Myeloma - Myelodysplastic Syndromes - Myelodysplastic-Myeloproliferative Diseases - Myeloproliferative Disorders - Neoplasms - Neoplasms, Plasma Cell - Neuroblastoma - Plasmacytoma - Preleukemia
Conditions: Keywords
recurrent childhood acute lymphoblastic leukemia, refractory multiple myeloma, recurrent childhood rhabdomyosarcoma, disseminated neuroblastoma, recurrent neuroblastoma, recurrent Wilms tumor and other childhood kidney tumors, recurrent childhood lymphoblastic lymphoma, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, recurrent childhood acute myeloid leukemia, relapsing chronic myelogenous leukemia, refractory chronic lymphocytic leukemia, chronic phase chronic myelogenous leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, primary myelofibrosis, childhood acute promyelocytic leukemia (M3), refractory hairy cell leukemia, oral complications, recurrent/refractory childhood Hodgkin lymphoma, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, pain, recurrent childhood small noncleaved cell lymphoma, recurrent childhood large cell lymphoma, previously treated childhood rhabdomyosarcoma, childhood malignant ovarian germ cell tumor, childhood chronic myelogenous leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, myelodysplastic/myeloproliferative neoplasm, unclassifiable, childhood myelodysplastic syndromes
Study Type
Study Phase
Phase 2
Study Design
Primary Purpose: Supportive Care
Name: management of therapy complications Type: Procedure
Name: pain therapy Type: Procedure
Overall Status
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth.

PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who are receiving chemotherapy with or without radiation therapy before donor bone marrow transplantation.
Detailed Description

- Compare the incidence and severity of oral mucositis in children undergoing NASA-developed light-emitting diode (LED) therapy during a pre-transplantation myeloablative conditioning regimen (chemotherapy with or without radiotherapy) and continuing through the post-bone marrow transplantation (BMT) phase versus LED therapy during the post-BMT phase only.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center and cheek being treated (right vs left). Patients are randomized to 1 of 2 schedules of light-emitting diode (LED) therapy.

- Arm I: Patients undergo LED therapy for 71 seconds once daily beginning on day 1 of the myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy and continuing for 14 days after bone marrow transplantation (BMT).

- Arm II: Patients undergo LED therapy as in arm I beginning on the day of BMT (day 0) and continuing for 14 days after BMT.

Photographs are taken of the right and left buccal mucosa at baseline and then every 3 days beginning on day 1 of LED therapy.

Pain and xerostomia are assessed using the Wong-Baker "smiley-face" pain scale at baseline and then periodically for 14 days after BMT.

Patients are followed monthly for 2 years.

PROJECTED ACCRUAL: A total of 80 patients (40 per arm) will be accrued for this study within 2 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 18 Years
Minimum Age: 2 Years
Gender: Both

- Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy prior to a first allogeneic bone marrow transplantation



- 2 to 18

Performance status:

- Not specified

Life expectancy:

- Not specified


- Not specified


- Not specified


- Not specified


- No pulmonary dysfunction that would increase significantly the risk of requiring intubation during the first 21 days after transplantation


- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

- No photophobia

- Must have emotional, cognitive, and mental maturity sufficient to tolerate light-emitting diode therapy application and oral examination without combativeness


Biologic therapy:

- See Disease Characteristics


- See Disease Characteristics

Endocrine therapy:

- Not specified


- See Disease Characteristics


- Not specified


- No concurrent medication that may cause epidermal or ocular photosensitivity
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Status: Recruiting
Contact: Clinical Trials Office - Medical College of Wisconsin Cancer C - 414-805-4380
Start Date
January 2002
Medical College of Wisconsin
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page